The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | Claudin 18.2 and FGFR2b as novel targets in gastric cancer
Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the development of novel targeted therapies for gastric cancer. In addition to microsatellite instability (MSI) high and PD-L1, claudin 18.2 and FGFR2b have been identified as promising targets. Zolbetuximab, and anti-claudin 18.2 antibody has improved survival in patients with gastric cancer in the Phase III SPOTLIGHT trial (NCT03504397). Bemarituzumab has additionally validated FGFR2b as a target in the first-line setting. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
